Syndax home

Entinostat for breast cancer. Entinostat for lung cancer. We are a late-stage biopharmaceutical company leveraging recent scientific insights on our lead therapeutic candidate entinostat in the emerging field of immuno-oncology. Due to its distinctive mechanism and preclinical and clinical activity observed to date, we believe entinostat holds great promise as a cornerstone combination therapy for a broad range of cancers.

OVERVIEW

This website syndax.com currently has a traffic classification of three hundred and thirty-four thousand seven hundred and thirty-two (the smaller the more traffic). We have researched fifteen pages inside the site syndax.com and found one hundred websites referring to syndax.com. I discovered two contacts and locations for syndax.com to help you correspond with them. This website syndax.com has been on the internet for one thousand and seventy-nine weeks, eight days, two hours, and nineteen minutes.
Traffic Rank
#334732
Pages Analyzed
15
Links to this site
100
Contacts
2
Locations
2
Online Since
Jun 2004

SYNDAX.COM RANKINGS

This website syndax.com has seen variant amounts of traffic for the duration of the year. Chiefly, the website had a ranking in the past 24 hours of three hundred and thirty-four thousand seven hundred and thirty-two.
Traffic for syndax.com

Date Range

1 week
1 month
3 months
This Year
Last Year
All time
Traffic ranking (by month) for syndax.com

Date Range

All time
This Year
Last Year
Traffic ranking by day of the week for syndax.com

Date Range

All time
This Year
Last Year
Last Month

SYNDAX.COM HISTORY

This website syndax.com was registered on June 29, 2004. This web page was changed on the date of July 19, 2007. This web page will go back on the market on June 29, 2015. As of today, it is one thousand and seventy-nine weeks, eight days, two hours, and nineteen minutes young.
REGISTERED
June
2004
UPDATED
July
2007
EXPIRED
June
2015

COMPANY AGE

20
YEARS
8
MONTHS
7
DAYS

LINKS TO BUSINESS

Investors Syndax

is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA.

WHAT DOES SYNDAX.COM LOOK LIKE?

Desktop Screenshot of syndax.com Mobile Screenshot of syndax.com Tablet Screenshot of syndax.com

CONTACTS

Syndax Pharmaceuticals

John Pallies

460 Totten Pond Rd Suite 650

Waltham, MA, 02451

US

Registercom

Domain Registrar

12808 Gran Bay Pkwy

West Jacksonville, FL, 32258

US

SYNDAX.COM HOST

I discovered that the main root page on syndax.com took two hundred and sixty-six milliseconds to stream. Our parsers could not discover a SSL certificate, so our crawlers consider this site not secure.
Load time
0.266 seconds
SSL
NOT SECURE
Internet Address
216.38.65.10

NAME SERVERS

ns1.tier1net.net
ns2.tier1net.net
ns4.tier1net.net

BOOKMARK ICON

SERVER OPERATING SYSTEM AND ENCODING

I diagnosed that this website is weilding the Microsoft-IIS/6.0 operating system.

TITLE

Syndax home

DESCRIPTION

Entinostat for breast cancer. Entinostat for lung cancer. We are a late-stage biopharmaceutical company leveraging recent scientific insights on our lead therapeutic candidate entinostat in the emerging field of immuno-oncology. Due to its distinctive mechanism and preclinical and clinical activity observed to date, we believe entinostat holds great promise as a cornerstone combination therapy for a broad range of cancers.

CONTENT

This website syndax.com had the following in the site, "We are a late-stage biopharmaceutical company leveraging recent scientific insights on our lead therapeutic candidate entinostat in the emerging field of immuno-oncology." Our analyzers viewed that the website stated " Due to its distinctive mechanism and preclinical and clinical activity observed to date, we believe entinostat holds great promise as a cornerstone combination therapy for a broad range of cancers."

SUBSEQUENT WEBSITES

SYNDAX Corporation - Part of YULAI Federation - EVE Online - A PVP Oriented Corp

We are a PvP Corporation flying under the NRDS policy.

SyndBank Services Limited

Data base for Bancassurance products, new products of banks, Tier-II bonds, etc.

Synergetics DCS

Thank you from Synergetics! .